NBRV Projected Dividend Yield
Nabriva Therapeutics Plc ( NASDAQ : NBRV )Nabriva Therapeutics is a holding company. Through its subsidiaries, Co. is a biopharmaceutical company engaged in the research, development and commercialization of anti-infective agents to treat serious infections. Co. has approval from the U.S. Food and Drug Administration for XENLETA for the treatment of adults with community-acquired bacterial pneumonia. XENLETA is an oral and intravenous treatment in the pleuromutilin class of antibiotics available for the systematic administration in humans. Co.'s CONTEPO is a potentially epoxide antibiotic for intravenous use in the U.S. for complicated urinary tract infections. Co. may develop XENLETA and CONTEPO for additional indications. 20 YEAR PERFORMANCE RESULTS |
NBRV Dividend History Detail NBRV Dividend News NBRV Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |